Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 2

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
)

    For
    the six months Ended June 30,

    2025

    2024

    CASH FLOWS FROM
    OPERATING ACTIVITIES:

    Net
    loss
     
    $
    (5,416,550
    )
     
    $
    (4,333,949
    )

    Adjustments
    to reconcile net loss to net cash used in operating activities

    Amortization of debt
    discount

    258,891

    605,630

    Stock-based compensation

    899,317

    751,530

    Changes in operating
    assets and liabilities:

    Accounts payable
    and accrued expenses

    3,102,476

    (1,481,113)

    Accrued compensation

    23,636

    (282,518
    ) 

    Due from Chromocell
    Corporation

    —

    (45,786
    )

    Prepaid expenses

    52,959

    (158,102
    )

    Net Cash Used In
    Operating Activities

    (1,079,271
    )

    (4,944,308
    )

    CASH FLOWS FROM
    FINANCING ACTIVITIES:

    Proceeds from loan
    payable, net of debt discount

    625,000

    1,455,416

    Proceeds from loan
    payable, net of debt discount - related party

    —

    131,868

    Payment
    of bridge loan, net of debt discount

    —

    (214,757
    )

    Common
    stock issued for cash

    —

    5,972,000

    Recission
    of common stock

    —

    (91,512
    ) 

    Net Cash Provided
    By Financing Activities

    625,000

    7,253,015

    NET CHANGE IN
    CASH

    (454,271
    ) 

    2,308,707

    CASH AT BEGINNING
    OF YEAR

    513,443

    96,391

    CASH AT END OF
    YEAR
     
    $
    59,172

    $
    2,405,098

    Supplemental
    cash flow information:

    Cash paid for income
    taxes
     
    $